Amgen (AMGN) closed the most recent trading day at $337.50, moving -2.05% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 1.62%. Meanwhile, the Dow ...

The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

Ethyreal Bio has exited stealth with $101 million, joining the queue of companies preparing to challenge Amgen’s Tepezza.

A mgen plans to invest more than $600 million in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California. The center is designed to bring ...

Amgen, Gilead Sciences and Regeneron Pharmaceuticals anchor big biotech with established therapies across inflammation, HIV, oncology and eye care.

Investors may be asking whether Amgen's share price still offers value at current levels, or if most of the opportunity is ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The Amgen Biotech Experience (ABE), a global initiative ...

Amgen is entering a pivotal period the as it moves beyond its Enbrel franchise and repositions around obesity, rare disease and next-generation oncology. While Enbrel has entered a period of decline ...

Biotech company Amgen is investing $600 million into a new research center for its Thousand Oaks campus. The new site will create hundreds of jobs and feature advanced automation and digital ...

US biotech major Amgen yesterday announced that the European Commission (EC) has granted marketing authorization for ...